(Reuters) – A Chinese coronavirus vaccine developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has been shown to be safe in the first clinical trial, researchers said.
In a Phase 1 trial of 191 healthy participants between the ages of 18 and 59, vaccination with the group’s test shot did not show a negative reaction, researchers said Tuesday in a paper submitted to a medRxiv preprint server prior to peer review.
The most common response reported by trial participants was mild pain, slight fatigue and redness, itching and swelling at the injection site.
The candidate also responded with a physical response.
“All the findings of this study support the safety and resilience of this inactive vaccine and are encouraging in terms of further studies of its effectiveness in the future,” the newspaper said.
China has inflicted hundreds of thousands of key workers and other groups considered to be a major threat to other policies, as even clinical trials have not been completely completed, raising safety concerns among experts.
China has at least four test targets in the final phase of clinical trials.